Church & Dwight to Buy Touchland Hand-Sanitizer Brand
Church & Dwight has struck a deal to buy the Touchland hand-sanitizer brand for up to $880 million.
Church & Dwight Co.: Increasingly Difficult To Justify Valuation Premium
I maintain a hold rating on Church & Dwight Co. due to weak domestic performance, retailer destocking, and new tariff headwinds impacting growth prospects. CHD's 1Q25 results showed a 2.4% decline in net sales and a 1.2% decrease in organic sales, driven by a 1.4% volume drop. The deteriorating US consumer environment and retailer inventory reductions are significant headwinds, with no expected recovery in the near term.
Church & Dwight Co., Inc. (CHD) Q1 2025 Earnings Call Transcript
Church & Dwight Co., Inc. (NYSE:CHD ) Q1 2025 Earnings Conference Call May 1, 2025 10:00 AM ET Company Participants Rick Dierker - President and Chief Executive Officer Lee McChesney - Chief Financial Officer Conference Call Participants Rupesh Parikh - Oppenheimer Anna Lizzul - Bank of America Chris Carey - Wells Fargo Andrea Teixeira - JPMorgan Steve Powers - Deutsche Bank Olivia Tong - Raymond James Peter Grom - UBS Lauren Lieberman - Barclays Korinne Wolfmeyer - Piper Sandler Kaumil Gajrawala - Jefferies Javier Escalante - Evercore Dara Mohsenian - Morgan Stanley Filippo Falorni - Citi Kevin Grundy - BNP Paribas Robert Moskow - TD Cowen Operator Good morning, ladies and gentlemen, and welcome to the Church & Dwight's First Quarter 2025 Earnings Conference Call. Before we begin, I have been asked to remind you that on this call, the company's management may make forward-looking statements regarding, among other things, the company's financial objectives and forecasts.
Church & Dwight Q1 Earnings Beat Estimates, Lower Organic Sales Hurt
CHD posts earnings beat in first-quarter 2025. Net sales dip 2.4% year over year on lower organic sales.
Church & Dwight (CHD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Church & Dwight (CHD) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Church & Dwight (CHD) Beats Q1 Earnings Estimates
Church & Dwight (CHD) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.89 per share. This compares to earnings of $0.96 per share a year ago.
What Analyst Projections for Key Metrics Reveal About Church & Dwight (CHD) Q1 Earnings
Besides Wall Street's top -and-bottom-line estimates for Church & Dwight (CHD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Church & Dwight to Report Q1 Earnings: What Investors Should Expect
CHD's Q1 results are likely to reflect gains from brand strength, while the dynamic consumer environment is concerning.
Church & Dwight (CHD) Expected to Beat Earnings Estimates: Should You Buy?
Church & Dwight (CHD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Best Stocks To Buy Now, While The Market Implodes Around Them (CHD, CLX, DEO, UL)
Things look pretty grim out there. Every single one of ‘The Magnificent Seven' stocks are in the red before the open, though MSFT only narrowly so.
Church & Dwight Stock Trading at a Premium: Time to Hold or Fold?
Church & Dwight Co., Inc. CHD is currently trading at a forward 12-month price-to-earnings multiple of 28.23x, which positions it at a premium compared with the industry's average of 20x. The valuation indicates that Church & Dwight is overvalued.
Church & Dwight: Solid Performance, But Valuation And Margin Concerns Remain
I maintain a neutral view on Church & Dwight Co. due to concerns about slowing domestic growth, which could impact its valuation multiples. Despite solid 4.2% organic sales growth in 4Q24, CHD's domestic segment grew only 2.7%, marking the 7th consecutive quarter of deceleration. Strong international performance and high demand for Hero and TheraBreath are positive, but domestic softness remains a significant risk.
